Exploring the Potentials of Antibody–siRNA Conjugates in Tumor Cell Gene Silencing without Cationic Assistance

Abstract excerpt

Antibody–siRNA conjugates (ARCs) are a type of promising drug modalities for cancer therapy. However, initial reports of ARCs present the gene knockdown effect only in limited tissues (e.g., muscles) or tumors of special targets (e.g., TenB2 and BCMA receptors). To expand the scope to more targets, herein we built structurally defined DAR2 ARCs and examined their effect on targeted gene silencing of tumor cells...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Advanced biosensing and bioanalysis techniques
• Share to Monoclonal and Polyclonal Antibodies Research
• Share to RNA Interference and Gene Delivery